Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 2,252 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider Rui Avelar sold 2,252 shares of Evolus stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $10.85, for a total value of $24,434.20. Following the transaction, the insider now owns 366,595 shares in the company, valued at approximately $3,977,555.75. The trade was a 0.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Evolus Trading Up 4.6 %

EOLS stock traded up $0.50 during mid-day trading on Thursday, hitting $11.35. 541,978 shares of the company were exchanged, compared to its average volume of 588,928. The business has a fifty day simple moving average of $13.56 and a 200-day simple moving average of $13.75. The firm has a market capitalization of $718.69 million, a P/E ratio of -12.47 and a beta of 1.27. Evolus, Inc. has a 12-month low of $9.80 and a 12-month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Analysts Set New Price Targets

EOLS has been the subject of several recent analyst reports. Barclays raised their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, September 13th. HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, November 7th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Evolus in a research note on Monday, September 16th.

Institutional Trading of Evolus

Institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new position in Evolus during the second quarter worth $43,000. Quarry LP acquired a new position in Evolus during the 2nd quarter worth about $54,000. Profund Advisors LLC acquired a new position in Evolus in the 2nd quarter valued at about $130,000. Point72 Asset Management L.P. acquired a new stake in shares of Evolus during the third quarter worth about $132,000. Finally, Arizona State Retirement System boosted its stake in shares of Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock valued at $158,000 after purchasing an additional 1,253 shares during the period. Institutional investors and hedge funds own 90.69% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.